feed

S&P 500—

NASDAQ—

DOW—

RUSSELL—

VIX—

US10Y—

DXY—

EUR/USD—

GBP/USD—

GOLD—

WTI—

BTC—

ETH—

AArphraTerminal

Arphra/Issuer/INCY

INCY

Incyte Corporation

HealthcareBiotechnologyUSUSD

$96.74

+0.28%Live · FMPMay 29, 2026

Market cap

$19.33B

52w range

63.93 – 112.29

P / E

—

EPS

—

Volume

2.9M

Revenue · FY

$5.14B

+21.22% YoY

Explain this page

Arphra AIPlain-English read on Incyte Corporation’s valuation

Press releasestopic:all earnings guidance dividend buyback mna ipo split layoffs lawsuit regulation rating executive product macro

News sentiment · 90d

DB · scored

2026-05-01 bullish neutral bearish2026-05-12

News

DB · scored8

Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress
May 12, 2026Business Wire
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress
May 12, 2026Business Wire
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis
May 07, 2026Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 06, 2026Business Wire
Why Incyte (INCY) is a Top Momentum Stock for the Long-Term+1.00
May 04, 2026Zacks Investment Research
New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1]+1.00
May 03, 2026PRNewsWire
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease+1.00
May 01, 2026Business Wire
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease+1.00
May 01, 2026Business Wire